Paresh Vyas

Active 1992–2025

139
Papers
27,698
Citations
82
h-index
136
i10-index

Citations

Citations per year for Paresh Vyas1990: 1 citations1993: 4 citations1994: 3 citations1995: 2 citations1996: 8 citations1997: 20 citations1998: 25 citations1999: 21 citations2000: 22 citations2001: 33 citations2002: 30 citations2003: 43 citations2004: 32 citations2005: 57 citations2006: 50 citations2007: 64 citations2008: 70 citations2009: 77 citations2010: 59 citations2011: 77 citations2012: 149 citations2013: 151 citations2014: 193 citations2015: 226 citations2016: 260 citations2017: 253 citations2018: 296 citations2019: 1,043 citations2020: 1,146 citations2021: 1,323 citations2022: 1,003 citations2023: 913 citations2024: 1,416 citations2025: 672 citations2026: 11 citations1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,408 citing papers, 27% of this breakdownUnited Kingdom: 1,082 citing papers, 8.6% of this breakdownGermany: 957 citing papers, 7.6% of this breakdownChina: 821 citing papers, 6.5% of this breakdownItaly: 754 citing papers, 6% of this breakdownFrance: 610 citing papers, 4.8% of this breakdownSpain: 427 citing papers, 3.4% of this breakdownCanada: 422 citing papers, 3.4% of this breakdownNetherlands: 384 citing papers, 3% of this breakdownAustralia: 349 citing papers, 2.8% of this breakdownJapan: 321 citing papers, 2.5% of this breakdownSwitzerland: 248 citing papers, 2% of this breakdown
0%27%Other 22.4%

Fields

  • Medicine63.6%
  • Biochemistry, Genetics and Molecular Biology28.2%
  • Immunology and Microbiology6.2%
  • Neuroscience0.5%
  • Computer Science0.3%
  • Chemistry0.3%
  • Other0.9%

Topics

  • Acute Myeloid Leukemia Research15.4%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment4.3%
  • Hematopoietic Stem Cell Transplantation3.8%
  • Epigenetics and DNA Methylation3.5%
  • Cancer Genomics and Diagnostics3.4%
  • Acute Lymphoblastic Leukemia research3%
  • Other66.6%

Coauthors

All papers

Open in search
  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard A. Larson, Michelle M. Le Beau, Mignon L. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte M. Niemeyer, Olatoyosi Odenike, Seishi Ogawa, Alberto Órfão, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching‐Hon Pui, Jerald P. Radich, Andreas Reiter, Marı́a Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt‐Graeff, Akiko Shimamura, Jorge Sierra, Wendy Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei‐Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi - Blood 2022 cited by 2,693

  2. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 1,469

  3. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2018 cited by 1,029

  4. Clinical and biological implications of driver mutations in myelodysplastic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony R. Green, Jacqueline Boultwood, Paresh Vyas, Eva Hellström‐Lindberg, David Bowen, Mario Cazzola, Michael R. Stratton, Peter J. Campbell - Blood 2013 cited by 1,832

  5. Assessment of Minimal Residual Disease in Standard-Risk AML

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 836

  6. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 171

  7. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana Dunshee, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, Alan F. List - New England Journal of Medicine 2020 cited by 537

  8. SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E. Joanna Baxter, J Score, Anna Gallì, Matteo Giovanni Della Porta, Erica Travaglino, Michael J. Groves, Sudhir Tauro, Nikhil C. Munshi, Kristina Anderson, Adel K. El‐Naggar, Andrej Fischer, Ville Mustonen, Alan J. Warren, Nicholas C.P. Cross, Anthony R. Green, P. Andrew Futreal, Michael R. Stratton, Peter J. Campbell - New England Journal of Medicine 2011 cited by 1,216

  9. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1 -Mutated Myeloid Malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Discovery 2023 cited by 122

  10. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 121

  11. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jack A. Taylor, D Neil Hayes, David Malkin, ICGC Breast Cancer Group, ICGC Chronic Myeloid Disorders Group, ICGC Prostate Cancer Group, Christopher S. Foster, Anne Y. Warren, Hayley C. Whitaker, Daniel S. Brewer, Rosalind A. Eeles, Colin Cooper, David E. Neal, Tapio Visakorpi, William B. Isaacs, G. Steven Bova, Adrienne M. Flanagan, P. Andrew Futreal, Andy G. Lynch, Patrick F. Chinnery, Ultan McDermott, Michael R. Stratton, Peter J. Campbell - eLife 2014 cited by 500

  12. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2015 cited by 353

  13. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 191

  14. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

    Authors: , , , , , , , , , - Blood 2013 cited by 324

  15. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Detlef Haase, Heinz Tüchler, Peter L. Greenberg, Seishi Ogawa, Eva Hellström‐Lindberg, Mario Cazzola - Blood 2020 cited by 293

  16. TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

    Authors: , , , , , , , , , - Cancer Discovery 2022 cited by 150

  17. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Medicine 2017 cited by 421

  18. Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tariq Enver, Sten Eirik W. Jacobsen, Catherine Porcher, Paresh Vyas - Cancer Cell 2011 cited by 640

  19. A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Tan, Jan Willem Thuring, Trevor Tucker, Paresh Vyas - Blood 2023 cited by 49

  20. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 165

  21. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 115

  22. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

    Authors: , , , , , , , , , , , , , , - Blood 2020 cited by 159

  23. Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell stem cell 2024 cited by 98

  24. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michaëla Fontenay, Olivier Kosmider, Michal Bar‐Natan, David P. Steensma, Richard M. Stone, Michael Heuser, Felicitas Thol, Mario Cazzola, Luca Malcovati, Aly Karsan, Christina Ganster, Eva Hellström‐Lindberg, Jacqueline Boultwood, Andrea Pellagatti, Valeria Santini, Lynn Quek, Paresh Vyas, Heinz Tüchler, Peter L. Greenberg, Rafael Bejar - Leukemia 2019 cited by 259